[go: up one dir, main page]

MX2010002406A - Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii. - Google Patents

Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.

Info

Publication number
MX2010002406A
MX2010002406A MX2010002406A MX2010002406A MX2010002406A MX 2010002406 A MX2010002406 A MX 2010002406A MX 2010002406 A MX2010002406 A MX 2010002406A MX 2010002406 A MX2010002406 A MX 2010002406A MX 2010002406 A MX2010002406 A MX 2010002406A
Authority
MX
Mexico
Prior art keywords
type
combination therapy
antibodies
cancer
antibody
Prior art date
Application number
MX2010002406A
Other languages
English (en)
Inventor
Pablo Umana
Thomas Friess
Christian Klein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38920778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010002406(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010002406A publication Critical patent/MX2010002406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invenci?n se refiere a la terapia de combinaci?n un anticuerpo anti-CD2O de tipo I y un anticuerpo anti-CD2O de tipo II para el tratamiento del c?ncer, especialmente de un c?ncer que expresa CD2O.
MX2010002406A 2007-09-05 2008-08-20 Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii. MX2010002406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07017337 2007-09-05
PCT/EP2008/006833 WO2009030368A1 (en) 2007-09-05 2008-08-20 Combination therapy with type i and type ii anti-cd20 antibodies

Publications (1)

Publication Number Publication Date
MX2010002406A true MX2010002406A (es) 2010-04-27

Family

ID=38920778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002406A MX2010002406A (es) 2007-09-05 2008-08-20 Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.

Country Status (16)

Country Link
US (5) US20110243931A1 (es)
EP (1) EP2197918B1 (es)
JP (1) JP5209723B2 (es)
KR (1) KR101234436B1 (es)
CN (1) CN101821292B (es)
AR (1) AR068818A1 (es)
AU (1) AU2008295140A1 (es)
BR (1) BRPI0816458A2 (es)
CA (1) CA2697482C (es)
CL (1) CL2008002613A1 (es)
ES (1) ES2449070T3 (es)
MX (1) MX2010002406A (es)
RU (1) RU2595383C2 (es)
TW (1) TW200918090A (es)
WO (1) WO2009030368A1 (es)
ZA (1) ZA201001442B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
BRPI0909227B8 (pt) * 2008-03-25 2021-05-25 Roche Glycart Ag uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR20130009760A (ko) * 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
EP2563391B1 (en) * 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
AR082693A1 (es) * 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
KR20130088170A (ko) * 2010-12-16 2013-08-07 로슈 글리카트 아게 비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2761294B1 (en) * 2011-09-29 2019-02-27 Meso Scale Technologies, LLC Biodosimetry panels and methods
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
CN105358177B (zh) 2013-04-17 2018-11-23 西格诺药品有限公司 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
US9119854B2 (en) 2013-05-03 2015-09-01 Celgene Corporation Methods for treating cancer using combination therapy
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3294771A1 (en) * 2015-05-11 2018-03-21 H. Hoffnabb-La Roche Ag Compositions and methods of treating lupus nephritis
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3630829A1 (en) * 2017-06-02 2020-04-08 H. Hoffnabb-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
HRP20250234T1 (hr) 2018-08-31 2025-04-11 Regeneron Pharmaceuticals, Inc. Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
NZ568769A (en) * 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
NZ582315A (en) 2003-01-22 2011-01-28 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
DK2380910T3 (en) * 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
AR055137A1 (es) 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada

Also Published As

Publication number Publication date
US20130195846A1 (en) 2013-08-01
CA2697482C (en) 2016-05-31
US20140294807A1 (en) 2014-10-02
CN101821292A (zh) 2010-09-01
CN101821292B (zh) 2014-03-26
EP2197918A1 (en) 2010-06-23
JP2010538024A (ja) 2010-12-09
EP2197918B1 (en) 2013-12-18
JP5209723B2 (ja) 2013-06-12
RU2595383C2 (ru) 2016-08-27
AU2008295140A1 (en) 2009-03-12
BRPI0816458A2 (pt) 2013-03-12
ES2449070T3 (es) 2014-03-18
WO2009030368A1 (en) 2009-03-12
RU2010112940A (ru) 2011-10-10
TW200918090A (en) 2009-05-01
CA2697482A1 (en) 2009-03-12
KR101234436B1 (ko) 2013-02-18
US20090060913A1 (en) 2009-03-05
CL2008002613A1 (es) 2009-10-16
US20120134990A1 (en) 2012-05-31
KR20100040325A (ko) 2010-04-19
AR068818A1 (es) 2009-12-09
ZA201001442B (en) 2013-08-28
US20110243931A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
MX2012001782A (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina.
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
AU2012335543A8 (en) HER3 antibodies and uses thereof
WO2014177615A3 (en) COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
NZ631197A (en) Anti sez6 antibodies and methods of use
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
PH12012502215A1 (en) Anti-fgfr2 antibodies
NZ597664A (en) Humanized anti-cdcp1 antibodies
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
EP4427805A3 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
NZ616382A (en) Antibodies specific to cadherin-17
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
EP2244735A4 (en) ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
PL2109623T3 (pl) Leczenie nowotworu przeciwciałami przeciw il-1
NZ607472A (en) Treatment for neoplastic diseases

Legal Events

Date Code Title Description
FG Grant or registration